Updated: 2-ArriVent’s oral lung cancer therapy fails in late-stage clinical trial, shares plunge
路透社2026/10/06 13:21In the first paragraph, stock information was added. Paragraphs 2 to 8 provide a detailed introduction to the disease and the clinical trial situation. Reuters, Oct. 6 - ArriVent BioPharma (AVBP.O) said on Tuesday that its oral therapy for treating rare lung cancer failed to meet its primary goal of delaying disease progression in a late-stage clinical trial, leading to its shares plunging by 63% in premarket trading. The therapy, firmonertinib, targets previously untreated advanced non-small cell lung cancer (NSCLC) patients who carry a gene mutation called the EGFR exon 20 insertion, which can promote cancer growth. This mutation accounts for about 0.5% to 1% of all NSCLC cases. NSCLC represents about 85% of all lung cancer cases. In the trial, according to independent reviewers, the 240mg dosage developed by ArriVent extended median progression-free survival to 11 months, compared to 9.5 months in the chemotherapy group. Chief Executive Officer Bing Yao stated that the improvement in progression-free survival (defined as the length of time patients live without worsening or spread of disease) was not significant. "These disappointing results are not what we had hoped for, especially for patients with EGFR exon 20 insertion-mutant NSCLC who are in urgent need of more effective treatments," said Yao. The company is evaluating the full data set to determine the most suitable development path for firmonertinib. ArriVent stated that no new safety signals were observed in the trial. The therapy has already been approved in China for non-small cell lung cancer patients carrying specific mutations. (For the convenience of non-English language speakers, Reuters has automated the translation of its reporting into several other languages. Due to possible errors or missing context in automated translation, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters accepts no responsibility for any damages or losses caused by the use of the automated translation feature.)
Additional stock information is included in paragraph 1; paragraphs 2 to 8 provide detailed information on the disease and clinical trial.
Reuters, October 6 - ArriVent BioPharma (AVBP.O) said on Tuesday that its oral therapy for the treatment of rare lung cancer failed to meet its primary goal of delaying disease progression in a late-stage clinical trial, sending the company's shares plunging 63% in premarket trading.
The therapy (firmonertinib) targets patients with previously untreated advanced non-small cell lung cancer (NSCLC) who carry a genetic alteration known as EGFR exon 20 insertion mutation, which may drive cancer growth.
This mutation accounts for about 0.5% to 1% of all NSCLC cases. Non-small cell lung cancer makes up about 85% of all lung cancer cases.
In the trial, according to an independent review, the 240-mg dose therapy developed by ArriVent extended median progression-free survival to 11 months, compared to 9.5 months for the chemotherapy group.
Chief Executive Officer Bing Yao said the improvement in progression-free survival—that is, the time patients live without disease worsening or spreading—was not significant.
“These disappointing results are not what we had hoped for, especially for patients with EGFR exon 20 insertion mutation NSCLC who are in urgent need of more effective treatment options.”
Yao said the company is evaluating the full data set to determine the most appropriate development path for firmonertinib.
ArriVent said no new safety signals were observed in the trial.
The therapy has already been approved in China for NSCLC patients carrying specific mutations.
(To assist non-English speakers, Reuters offers its reports through automated translation into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the translated text, which is provided solely for the convenience of readers. Reuters accepts no liability for any damage or loss arising from the use of this automated translation service.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BAE Systems wins Lockheed Martin contract to supply electronic warfare systems for F-35 jets
BAE Systems won a Lockheed Martin contract to supply electronic warfare systems for F-35 Lightning II fighter jets. Order covers production deliveries for F-35 Lots 20-22. Deal also includes retrofit systems to modernize older aircraft in the global F-35 fleet. BAE Systems has delivered more than 1,500 F-35 electronic warfare systems to date. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BAE Systems plc published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610061000PR_NEWS_USPR_____NE64821) on October 06, 2026, and is solely responsible for the information contained therein.
BUZZ-AMC shares rise after completing $3.97 billion debt refinancing
On October 6, cinema chain AMC Entertainment (AMC.N) shares rose 3.5% to $2.89. AMC completed a $3.97 billions refinancing, covering about 97% of its debt. The transaction extends the maturity dates of nearly all its debt to October 2031 and October 2033, and reduces its capital costs. The company repaid its existing term loans and refinanced debt maturing in 2029, thereby simplifying its capital structure. AMC’s new loan structure includes $2 billions of first-lien notes maturing in 2031, $850 millions of first-lien term loans, and $1.12 billions of second-lien loans from the Deutsche Bank’s Special Situations Group. Proceeds from the deal will be used to repay several debts maturing in 2029 and 2027, as well as to provide loans to its subsidiary Odeon Finco. AMC has reported annual net losses every year since 2018, which has compounded its heavy debt burden and financing costs. As of the last trading day’s close, AMC shares have increased 83.65% so far this year.
Morgan Stanley: Space is the "ultimate backyard" for computing power, maintains "Overweight" rating on SpaceX (SPCX.US)
Morgan Stanley maintains an "Overweight" rating on SpaceX with a target price of $300, stating that space is the ultimate scenario for AI computing power and that the renaming to SpaceXSI reflects ambitions for superintelligence.
Japanese Yen: Range trade holds against US Dollar as Fed path questioned – Rabobank
Crypto prices
More
